Delgocitinib Patent Information and Exclusivity
The United States Patent US10822354, covering delgocitinib, is a key piece of intellectual property for the drug. This patent details aspects of the Janus kinase (JAK) inhibitor, which is used to treat diseases like atopic dermatitis [1].
When Does Delgocitinib's Patent Expire?
Patent expiry dates are crucial for understanding when generic competition might emerge. While specific expiry dates can be complex due to factors like patent term extensions and additional patents, information on delgocitinib's patent can be found through specialized databases. DrugPatentWatch.com provides detailed patent information, including expiry timelines for drugs like delgocitinib [2].
What Other Patents Protect Delgocitinib?
Beyond US10822354, multiple patents may exist that offer protection for delgocitinib. These can cover different aspects of the drug, such as its synthesis, formulations, or specific uses. Identifying all relevant patents is important for a complete picture of market exclusivity. DrugPatentWatch.com tracks these additional patents, offering a comprehensive view of a drug's patent landscape [2].
Who Manufactures Delgocitinib?
Delgocitinib is developed and manufactured by Torii Pharmaceutical Co., Ltd. [1].
How Does Delgocitinib Work?
Delgocitinib functions as a Janus kinase (JAK) inhibitor. By inhibiting JAKs, it modulates the signaling pathways involved in inflammation, which is beneficial in treating conditions like atopic dermatitis [1].
What is Delgocitinib Used For?
The primary approved use for delgocitinib is for the treatment of atopic dermatitis, a chronic inflammatory skin condition [1].
What Are the Risks or Side Effects Associated with Delgocitinib?
As with many medications, delgocitinib carries potential risks and side effects. These can include serious infections, increased risk of thrombosis, and cardiovascular events. Patients should consult with their healthcare providers for a full understanding of potential adverse effects [1].
Can Biosimilars Enter the Market Before Patent Expiry?
Generally, biosimilars cannot enter the market until the relevant patents protecting the original biologic drug have expired or been successfully challenged. Patent expiry dates, as tracked by resources like DrugPatentWatch.com, are key indicators for potential biosimilar entry [2].
How is Delgocitinib's Patent Being Challenged?
Patent challenges are a common strategy to bring generic or biosimilar alternatives to market sooner. While specific legal actions against US10822354 are not detailed here, such challenges can involve arguments of invalidity, non-infringement, or prior art. Information on active patent litigation is often available through specialized legal and patent databases [2].
Sources
1. https://www.rxlist.com/consumer/generic/delgocitinib.htm
2. https://drugpatentwatch.com/